Skip to Content
UW Health SMPH
American Family Children's Hospital
SHARE TEXT

ibritumomab

Pronunciation: ib ri TYOO mo mab

Brand: In-111 Zevalin, Y-90 Zevalin

What is the most important information I should know about ibritumomab?

Multum nopreg

Do not receive this medication if you are pregnant. It could cause harm to the unborn baby. Use an effective form of birth control, and tell your doctor if you become pregnant during treatment.

Multum emt

Ibritumomab can lower blood cells that help your body fight infections. Your blood may need to be tested often. Avoid being near people who are sick or have infections. Avoid activities that may increase your risk of bleeding injury. Tell your doctor at once if you develop signs of infection.

Multum donot

Do not receive a "live" vaccine while you are being treated with ibritumomab, and avoid coming into contact with anyone who has recently received a live vaccine. There is a chance that the virus could be passed on to you.

Some people receiving ibritumomab have developed "secondary" bone marrow or blood cell cancers such as leukemia. Talk with your doctor about your individual risk while receiving this medication.

What is ibritumomab?

Ibritumomab is a protein that targets white blood cells in the body. When ibritumomab is attached to a radioactive chemical, the radiation is delivered directly to the tumor (lymphoma).

Ibritumomab is used in combination with other medicines to treat non-Hodgkin's lymphoma.

Ibritumomab may also be used for purposes than those listed in this medication guide.

What should I discuss with my healthcare provider before receiving ibritumomab?

Multum donot

You should not receive this medication if you are allergic to ibritumomab, or to radioactive chemicals or mouse proteins.

To make sure you can safely take ibritumomab, tell your doctor if you have any of these other conditions:

  • liver disease;
  • kidney disease;
  • any type of infection;
  • lung or breathing problems;
  • bleeding or blood clotting problems;
  • low platelet counts;
  • low blood pressure; or
  • a history of heart disease, heart attack, angina (chest pain), or irregular heart beats.

Some people receiving ibritumomab have developed "secondary" bone marrow or blood cell cancers such as leukemia. Talk with your doctor about your individual risk while receiving this medication.

Multum emt

Ibritumomab is made from human plasma (part of the blood) which may contain viruses and other infectious agents. Donated plasma is tested and treated to reduce the risk of it containing infectious agents, but there is still a small possibility it could transmit disease. Talk with your doctor about the risks and benefits of using this medication.

Multum nopreg

FDA pregnancy category D. Do not use ibritumomab if you are pregnant. It could harm the unborn baby. Use effective birth control, and tell your doctor if you become pregnant during treatment.

Multum nobrfeed

It is not known whether ibritumomab passes into breast milk or if it could harm a nursing baby. Do not receive ibritumomab without telling your doctor if you are breast-feeding a baby.

How is ibritumomab given?

Ibritumomab is used in combination with rituximab (Rituxan) and a radioactive chemical. Ibritumomab is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting.

Ibritumomab is usually given every 7 to 9 days. Follow your doctor's instructions.

Multum emt

Ibritumomab can lower blood cells that help your body fight infections. This can make it easier for you to bleed from an injury or get sick from being around others who are ill. Your blood may need to be tested often. Visit your doctor regularly.

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your ibritumomab injection.

What happens if I overdose?

Multum emt

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include weakness, pale skin, and easy bruising or bleeding.

What should I avoid while receiving ibritumomab?

Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.

Multum donot

Do not receive a "live" vaccine while using ibritumomab, and avoid coming into contact with anyone who has recently received a live vaccine. There is a chance that the virus could be passed on to you. Live vaccines include measles, mumps, rubella (MMR), Bacillus Calmette-Guérin (BCG), oral polio, rotavirus, smallpox, typhoid, yellow fever, varicella (chickenpox), H1N1 influenza, and nasal flu vaccine.

What are the possible side effects of ibritumomab?

Multum emt

Some people receiving an ibritumomab injection have had a reaction to the infusion (when the medicine is injected into the vein). Tell your caregiver right away if you feel dizzy, nauseated, light-headed, sweaty, itchy, or have a fast heartbeat, trouble breathing, chest pain or heavy feeling, or pain spreading to the arm or shoulder. These reactions can occur during the injection or within 24 hours afterward.

Multum emt

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Multum donot

Call your doctor at once if you have a serious side effect such as:

  • pain, burning, redness, or skin changes where the medicine was injected;
  • fever with chills, body aches, and other flu symptoms;
  • easy bruising or bleeding, unusual weakness;
  • white patches or sores inside your mouth or on your lips; or
  • severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.

Less serious side effects may include:

  • nausea, vomiting, loss of appetite;
  • anxiety;
  • dizziness; or
  • joint pain.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect ibritumomab?

Before receiving ibritumomab, tell your doctor if you are using any type of blood thinner or medication used to prevent blood clots, such as:

  • abciximab (ReoPro)
  • alteplase (Activase);
  • anagrelide (Agrylin);
  • argatroban (Acova);
  • aspirin;
  • bivalirudin (Angiomax)
  • cilostazol (Pletal);
  • clopidogrel (Plavix);
  • dabigatran (Pradaxa);
  • dalteparin (Fragmin);
  • dipyridamole (Persantine, Aggrenox);
  • enoxaparin (Lovenox)
  • eptifibatide (Integrelin);
  • fondaparinux (Arixtra);
  • lepirudin (Refludan);
  • prasugrel (Effient);
  • rivaroxaban (Xarelto);
  • tenecteplase (TNKase);
  • ticlopidine (Ticlid);
  • tinzaparin (Innohep);
  • tirofiban (Aggrastat);
  • urokinase (Abbokinase); or
  • warfarin (Coumadin, Jantoven).

This list is not complete and there may be other drugs that can interact with ibritumomab. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

Where can I get more information?

Your doctor or pharmacist can provide more information about ibritumomab.


Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Every effort has been made to ensure that the information provided by Cerner Multum, Inc. ('Multum') is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Multum information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Multum does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Multum's drug information does not endorse drugs, diagnose patients or recommend therapy. Multum's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Multum does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 1996-2013 Cerner Multum, Inc. Version: 4.02. Revision date: 3/21/2012.

Your use of the content provided in this service indicates that you have read, understood and agree to the End-User License Agreement, which can be accessed by clicking on this link.

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.